Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hangzhou Zheda Dixun Biological Gene Engineering Co. Ltd. is a company patent portfolio with 1 pending office action. This matter is classified within the Biotechnology & Pharmaceuticals technology area. The prosecution is handled by 1 distinct examiner, which indicates a single point of contact for the current workload. The data identifies 1 distinct art unit associated with this portfolio.
GOLDBERG, JEANINE ANNE is the busiest examiner for this entity, with 1 pending office action currently assigned. This examiner's workload represents the entirety of the company's current pending office actions. The 1 distinct art unit shows that the technical subject matter is being evaluated within one specific section of the patent office. This concentration suggests that the technical review is not distributed across multiple examination groups.
The 1 distinct examiner is the only official listed for the pending matters. This means that the prosecution of the Biotechnology & Pharmaceuticals filings does not currently involve multiple examiners or different art units. The data reflects a portfolio with a single active office action response required at this time. Practitioners can focus their strategy on the specific requirements of the 1 art unit involved in the examination.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOLDBERG, JEANINE ANNE | 1 | 45.4% | +40.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18282157 | PRIMER PROBE SET FOR HUMAN HISTAMINE RECEPTOR HRH1 MRNA DETECTION, KIT AND DETECTION METHOD | GOLDBERG, JEANINE ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18282157 | PRIMER PROBE SET FOR HUMAN HISTAMINE RECEPTOR HRH1 MRNA DETECTION, KIT AND DETECTION METHOD | GOLDBERG, JEANINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18282157 | PRIMER PROBE SET FOR HUMAN HISTAMINE RECEPTOR HRH1 MRNA DETECTION, KIT AND DETECTION METHOD | GOLDBERG, JEANINE ANNE | 1682 | §103§112 | Final Rejection | — | Pending | Sep 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHangzhou Zheda Dixun Biological Gene Engineering Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jeanine Anne Goldberg has the most, with 1 of Hangzhou Zheda Dixun Biological Gene Engineering Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
